(Q43750671)

26 November 2017

title

Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation (English)

1 reference

26 November 2017

1 reference

0 references

1 reference

Shishoo CJ

1

1 reference

26 November 2017

Shah SA

2

1 reference

26 November 2017

Rathod IS

3

1 reference

26 November 2017

Savale SS

4

1 reference

26 November 2017

Vora MJ

5

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

International Journal of Pharmaceutics

26 November 2017

published in

1 reference

26 November 2017

volume

228

1 reference

26 November 2017

issue

1-2

1 reference

26 November 2017

page(s)

53-67

1 reference

Conjugated Estrogens Bioinequivalence: Comparison of Four Products in Postmenopausal Women

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900831-6

7 January 2021

Bioequivalence study of paracetamol tablets: in vitro-in vivo correlation

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900831-6

7 January 2021

Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin: Adsorption of rifampicin by an excipient, bentonite

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900831-6

7 January 2021

Drug combinations and the bioavailability of rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900831-6

7 January 2021

Serum concentrations and bioavailability of rifampicin and isoniazid in combination

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900831-6

7 January 2021

Solubility and dissolution properties of generic rifampicin raw materials

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900831-6

7 January 2021

The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900831-6

7 January 2021

Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900831-6

7 January 2021

Blood levels of rifampicin, desacetylrifampicin and isoniazid during combined therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900831-6

7 January 2021

Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900831-6

7 January 2021

Stability of rifampicin in dissolution medium in presence of isoniazid

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900831-6

7 January 2021

Bioavailability of Chlorothiazide Tablets in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900831-6

7 January 2021

10.1016/S0378-5173(01)00831-6

Identifiers

DOI

1 reference

26 November 2017

1 reference